Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Alantos Pharmaceuticals Holding, Inc.

Alantos Pharmaceuticals Holding, Inc. Patent applications
Patent application numberTitlePublished
20120015920HETEROBICYCLIC METALLOPROTEASE INHIBITORS - The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.01-19-2012
20110112051Dipeptidyl Peptidase-IV Inhibitors - The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.05-12-2011
20100009961DIPEPTIDYL PEPTIDASE-IV INHIBITORS - The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.01-14-2010
20090312312Heterobicyclic Metalloprotease Inhibitors - The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.12-17-2009

Patent applications by Alantos Pharmaceuticals Holding, Inc.